Docteur QUOC-VUONG DANG

Rhumatologue

RPPS 10003994208

🏆 1 DU/DIU

✨ Profil synthétique

IA · 10/05/2026

Le Docteur QUOC-VUONG DANG est un rhumatologue titulaire d'un DIU en Échographie générale. Ses publications sur PubMed couvrent des sujets tels que les csDMARDs, l'intelligence artificielle en rhumatologie, l'économie de la santé et l'épidémiologie. Il contribue également à des registres et des études épidémiologiques.

Expertises présumées

Échographie musculosquelettique
Traitement des maladies rhumatismales par csDMARDs
Intelligence artificielle en rhumatologie
Épidémiologie des maladies rhumatismales
Économie de la santé en rhumatologie
Gestion des données de santé
Analyse de registres de santé

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Diplômes

🎓 DES & spécialité ordinale

Rhumatologie (SM)

🏅 DU / DIU

DIU Echographie générale

📚 CES (Certificat d'Études Spéciales)

CES Rhumatologie

🎓 Diplômes

DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis

International immunopharmacology · 2018

📚 229 citations🎯 RCR 9.99Top 3% NIH

Human Chondrocytes from Human Adipose Tissue-Derived Mesenchymal Stem Cells Seeded on a Dermal-Derived Collagen Matrix Sheet: Our Preliminary Results for a Ready to Go Biotechnological Cartilage Graft in Clinical Practice

Stem cells international · 2021

📚 24 citations🎯 RCR 2.89Top 17% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Background. The articular cartilage is unique in that it contains only a single type of cell and shows poor ability for spontaneous healing. Cartilage tissue engineering which uses mesenchymal stem cells (MSCs) and adipose tissue-derived mesenchymal stem cells (AT-MSCs) is considered an attractive treatment for cartilage lesions and osteoarthritis. The establishment of cartilage regenerative medicine is an important clinical issue, but the search for cell sources able to restore cartilage integrity proves to be challenging. The aim of this study was to create cartilage grafts from the combination of AT-MSCs and collagen substrates. Methods. Mesenchymal stem cells were obtained from human donors’ adipose tissue, and collagen scaffold, obtained from human skin and cleaned from blood vessels, adipose tissues, and debris, which only preserve dermis and epidermis, were seeded and cultured on collagen substrates and differentiated to chondrocytes. The obtained chondrocyte extracellular matrix of cartilage was then evaluated for the expression of chondrocyte-/cartilage-specific markers, the Cartilage Oligomeric Matrix Protein (COMP), collagen X, alpha-1 polypeptide (COL10A1), and the Collagen II, Human Tagged ORF Clone (COL2A1) by using the reverse transcription polymerase chain reaction (RT-PCR). Results. Our findings have shown that the dermal collagen may exert important effects on the quality of in vitro expanded chondrocytes, leading in this way that the influence of collagen skin matrix helps to produce highly active and functional chondrocytes for long-term cartilage tissue regeneration. Conclusion. This research opens up the possibility of generating cartilage grafts with the precise purpose of improving the existing limitation in current clinical procedures.

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update

International journal of molecular sciences · 2023

📚 23 citations🎯 RCR 2.55Top 20% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

With the aging of the population, malignancies are becoming common complications in patients with rheumatoid arthritis (RA), particularly in elderly patients. Such malignancies often interfere with RA treatment. Among several therapeutic agents, immune checkpoint inhibitors (ICIs) which antagonize immunological brakes on T lymphocytes have emerged as a promising treatment option for a variety of malignancies. In parallel, evidence has accumulated that ICIs are associated with numerous immune-related adverse events (irAEs), such as hypophysitis, myocarditis, pneumonitis, and colitis. Moreover, ICIs not only exacerbate pre-existing autoimmune diseases, but also cause de novo rheumatic disease–like symptoms, such as arthritis, myositis, and vasculitis, which are currently termed rheumatic irAEs. Rheumatic irAEs differ from classical rheumatic diseases in multiple aspects, and treatment should be individualized based on the severity. Close collaboration with oncologists is critical for preventing irreversible organ damage. This review summarizes the current evidence regarding the mechanisms and management of rheumatic irAEs with focus on arthritis, myositis, and vasculitis. Based on these findings, potential therapeutic strategies against rheumatic irAEs are discussed.

Cookies & analyse de trafic

Docteur QUOC-VUONG DANG

Pourquoi vous devez consulter ce praticien

Diplômes

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (19) — classées par pathologie

Transversal13

csDMARDs2

IA en rhumatologie2

Économie santé1

Épidémiologie & registres1

Partager cette fiche